286 related articles for article (PubMed ID: 9528999)
1. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089.
VanWeelden K; Flanagan L; Binderup L; Tenniswood M; Welsh J
Endocrinology; 1998 Apr; 139(4):2102-10. PubMed ID: 9528999
[TBL] [Abstract][Full Text] [Related]
2. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro.
James SY; Mercer E; Brady M; Binderup L; Colston KW
Br J Pharmacol; 1998 Nov; 125(5):953-62. PubMed ID: 9846632
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells.
Simboli-Campbell M; Narvaez CJ; van Weelden K; Tenniswood M; Welsh J
Breast Cancer Res Treat; 1997 Jan; 42(1):31-41. PubMed ID: 9116316
[TBL] [Abstract][Full Text] [Related]
4. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089.
Zhang X; Jiang F; Li P; Li C; Ma Q; Nicosia SV; Bai W
Clin Cancer Res; 2005 Jan; 11(1):323-8. PubMed ID: 15671562
[TBL] [Abstract][Full Text] [Related]
5. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells.
James SY; Mackay AG; Colston KW
J Steroid Biochem Mol Biol; 1996 Jul; 58(4):395-401. PubMed ID: 8903423
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a vitamin D3-resistant MCF-7 cell line.
Narvaez CJ; Vanweelden K; Byrne I; Welsh J
Endocrinology; 1996 Feb; 137(2):400-9. PubMed ID: 8593782
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo.
Valrance ME; Brunet AH; Welsh J
Endocrinology; 2007 Oct; 148(10):4887-94. PubMed ID: 17628009
[TBL] [Abstract][Full Text] [Related]
8. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
Haq M; Kremer R; Goltzman D; Rabbani SA
J Clin Invest; 1993 Jun; 91(6):2416-22. PubMed ID: 8514854
[TBL] [Abstract][Full Text] [Related]
9. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro.
Colston KW; Mackay AG; James SY; Binderup L; Chander S; Coombes RC
Biochem Pharmacol; 1992 Dec; 44(12):2273-80. PubMed ID: 1472092
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
Lokeshwar BL; Schwartz GG; Selzer MG; Burnstein KL; Zhuang SH; Block NL; Binderup L
Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy.
Díaz GD; Paraskeva C; Thomas MG; Binderup L; Hague A
Cancer Res; 2000 Apr; 60(8):2304-12. PubMed ID: 10786699
[TBL] [Abstract][Full Text] [Related]
12. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo.
Koshizuka K; Koike M; Asou H; Cho SK; Stephen T; Rude RK; Binderup L; Uskokovic M; Koeffler HP
Breast Cancer Res Treat; 1999 Jan; 53(2):113-20. PubMed ID: 10326788
[TBL] [Abstract][Full Text] [Related]
13. EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer.
Milliken EL; Zhang X; Flask C; Duerk JL; MacDonald PN; Keri RA
Cancer Lett; 2005 Nov; 229(2):205-15. PubMed ID: 16115727
[TBL] [Abstract][Full Text] [Related]
14. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia.
Abe J; Nakano T; Nishii Y; Matsumoto T; Ogata E; Ikeda K
Endocrinology; 1991 Aug; 129(2):832-7. PubMed ID: 1855478
[TBL] [Abstract][Full Text] [Related]
15. The combination of a potent vitamin D3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice.
Sundaram S; Sea A; Feldman S; Strawbridge R; Hoopes PJ; Demidenko E; Binderup L; Gewirtz DA
Clin Cancer Res; 2003 Jun; 9(6):2350-6. PubMed ID: 12796405
[TBL] [Abstract][Full Text] [Related]
16. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.
Akutsu N; Lin R; Bastien Y; Bestawros A; Enepekides DJ; Black MJ; White JH
Mol Endocrinol; 2001 Jul; 15(7):1127-39. PubMed ID: 11435613
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen.
Vink-van Wijngaarden T; Pols HA; Buurman CJ; van den Bemd GJ; Dorssers LC; Birkenhäger JC; van Leeuwen JP
Cancer Res; 1994 Nov; 54(21):5711-7. PubMed ID: 7923220
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant.
Narvaez CJ; Welsh J
Endocrinology; 1997 Nov; 138(11):4690-8. PubMed ID: 9348195
[TBL] [Abstract][Full Text] [Related]
19. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer.
El Abdaimi K; Papavasiliou V; Rabbani SA; Rhim JS; Goltzman D; Kremer R
Cancer Res; 1999 Jul; 59(14):3325-8. PubMed ID: 10416587
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model.
Akhter J; Chen X; Bowrey P; Bolton EJ; Morris DL
Dis Colon Rectum; 1997 Mar; 40(3):317-21. PubMed ID: 9118747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
